Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Inclusion Criteria

• •For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
• •For RRMM participants who have received at least one prior line of therapy (LoT) for MM:
• •Have documented progression from a prior LoT
• •Participants who have initiated treatment with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
• •IMiDs
• •PIs
• •Combination of IMiD + PI
• •Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)
• •For NDMM participants receiving frontline therapy:
• •Eligible to receive frontline therapy for MM (no prior MM treatment)
• •Participants who have initiated treatment for MM with one of the following therapies within 90 days before consent for this study OR in the case where treatment has not yet been initiated, documentation that the treatment strategy was determined before consent for this study must be provided, and treatment must be initiated within 30 days after consent:
• •IMiDs
• •PIs
• •Combination of IMiD + PI
• •Newer agents with novel MOAs alone or in combination (eg, mAbs, HDACIs, Akt inhibitors, SINE, or CAR T-cell therapies)